Aerosolized amiloride: Dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 10, Issue 2, 1997, Pages 147-158

  Hofmann, Thomas ^a   Senier, Ivonne ^a   Bittner, Peter ^a   Hüls, Gerd ^a   Schwandt, Hans Joachim ^a   Lindemann, Hermann ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Aerosolized amiloride; High dose amiloride; Serum Amiloride level; Transepithelial potential difference

Indexed keywords

AMILORIDE;

ADOLESCENT; ADULT; AEROSOL; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG UPTAKE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SPUTUM;

EID: 0030982349     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.1997.10.147     Document Type: Article

References (24)

1. Boucher, R.C. 1994. Human airway ion transport (part two) [review]. Am. J. Respir. Crit. Care Med. 150:581-93.
2. Knowles, M., J. Gatzy, and R. Boucher. 1981. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N. Engl. J. Med. 305:1489-1495.
3. Hofmann, T. 1994. Kindgerechte Bestimmung der transepithelialen Potentialdifferenz am respiratorischen Epithel der Nase [thesis]: Mikroedition Verlag Hänsel-Hohenhausen 1995, Frankfurt.
4. Köhler, D., E. App, M. Schmitz-Schumann, G. Würtemberger, and H. Matthys. 1986. Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibrosis. Eur. J. Respir. Dis. 69:319-326.
5. Knowles, M.R., N.L. Church, W.E. Waltner, J.R. Yankaskas, P. Gilligan, M. King, L.J. Edwards, R.W. Helms, and R.C. Boucher. 1990. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N. Engl. J. Med. 322:1189-1194.
6. Lindemann, H., T. Becker, P. Bittner, A. Boldt, T. Hofmann, and H.J. Schwandt. 1990. Sekrete-limination bei CF-Patienten unter Amiloridinhalation. Pneumologie 44:1148-1150.
7. Tomkiewicz, R.P., E.M. App, J.G. Zayas, O. Ramirez, N. Church, R.C. Boucher, M.R. Knowles, and M. King. 1993. Amiloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration, and rheology of sputum. Am. Rev. Respir. Dis. 148:1002-1007.
8. Graham, A., A. Hasani, E.W.F.W. Alton, G.P. Martin, C. Marriott, M.E. Hodson, S.W. Clarke, and D.M. Geddes. 1993. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur. Respir. J. 6:1243-1248.
9. Pons, G., M.C. Marchand, C. Foucard, P. Chaumet-Riffaud, P. d'Athis, G. Lenoir, J. Navarro, and A. Sautejeau. 1995. French multicentre randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients [abstract]. Pediatr. Pulmonol. 12:193.
10. Knowles, M.R., J.L. Carson, A.M. Collier, J.T. Gatzy, and R.C. Boucher. 1981. Measurement of nasal transepithelial electric potential differences in normal human subjects in vivo. Am. Rev. Respir. Dis. 124:484-490.
11. Dab, I., and F. Alexander. 1979. The mechanism of autogenic drainage studied with flow volume curves. Monogr. Paediatr. 10:50-53.
12. Mead, R. 1988. Cross-over designs for residual on interaction effects. In R. Mead, ed. Statistical Principles for Practical Application. Cambridge University Press, Cambridge, 201-208.
13. Hofmann, T., G. Hüls, K. Schäfer, I. Senier, and H. Lindemann. 1992. Epicutaneous nasal potential difference: Influence of aerosolized amiloride in CF-patients. In Proceedings of the XIth International Cystic Fibrosis Congress, Dublin (Ireland), MP45.
14. Knowles, M.R., J. Gatzy, and R.C. Boucher. 1983. Relative ion permeability of normal and cystic fibrosis nasal epithelium. J. Clin. Invest. 71:1410-1418.
15. Knowles, M.R., N.L. Church, W.E. Waltner, J.T. Gatzy, and R.C. Boucher. 1992. Amiloride in cystic fibrosis: Safety, pharmacokinetics, and efficacy in the treatment of pulmonary disease. In T. Kleyman and E. Cragoe, eds. Amiloride and Its Analogs: Unique Cation Transport Inhibitors. VCH Publishers, New York, 301-313.
16. Lindemann, H. 1988. Indikationen und Formen der inhalativen Therapie. In G. Schultze-Werninghaus, and M. Debelic, eds. Asthma. Springer, Berlin, 348-356.
17. Anderson, W.H. 1993. Pharmacokinetics of amiloride by inhalation in adults, adolescents, and children. Presented at the 19th Cystic Fibrosis Conference. Madrid, Spain, May 21-26.
18. Knauf, H., K. Reuter, and E. Mutschler. 1985. Limitation on the use of amiloride in early renal failure. Eur. J. Clin. Pharmacol. 28:61-66.
19. Rolfe, M.W., S.L. Kunkel, B. Rowens, T.J. Standiford, E.J. Cragoe, Jr., and R.M. Strieter. 1992. Suppression of human alveolar macrophage-derived cytokines by amiloride. Am. J. Respir. Cell Mol. Biol. 6:576-582.
20. Lindemann, H. 1993. Aerosol treatment of cystic fibrosis-amiloride: Does it work? J. Aerosol Med. 6(Suppl):A108 [abstract].
21. Eschenbacher, W.L., H.A. Boushey, and D. Sheppard. 1984. Alteration of inhaled aerosols causes bronchoconstriction and cough, but absence of a permanent anion causes cough alone. Am. Rev. Respir. Dis. 192:211-215.
22. Knoch, M. 1994. A new nebulizer system for gentle warming of aerosol. J. Aerosol. Med. 7:300.
23. Hofmann, T., A. Ziersch, I. Senier, U. Blank, W.M. Weber, G. Hüls, and H. Lindemann. 1996. In vivo effects of benzamil and amiloride on nasal potential difference in CF respiratory epithelium. Isr J. Med. Sci. 32(Suppl):S190 [abstract].
24. Knowles, M.R., L.L. Clarke, and R.C. Boucher. 1991. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N. Engl. J. Med. 325:533-538.